Please assess the completion status of the following clinical trial:

Trial Title: Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed multiple myeloma~  * M-protein by serum protein electrophoresis or urine protein electrophoresis~ * Quantitative determination of immunoglobulin~ * Bone marrow biopsy and aspirate with a plasma cell count greater than 10%~ * Refractory or chemoresistant disease defined as failure to respond (less than 50% reduction in M protein level) or progression within 2 months after receiving at least 2 chemotherapy regimens including:~    * Alkylating based regimen (melphalan) in combination with steroids (prednisone) or other chemotherapy regimens (e.g., vincristine, bleomycin, melphalan, cyclophosphamide, and prednisone or vincristine, carmustine, doxorubicin, and prednisone)~   * Vincristine, doxorubicin, and dexamethasone (VAD) regimen~   * Pulse therapy with high dose steroids alone~   * High dose alkylating agent and autologous stem cell transplantation~   * Allogeneic bone marrow transplantation~ * Plateau phase defined as M protein in the serum or urine for more than 6 weeks despite response to prior therapy~    * Must have received at least 2 of the chemotherapy regimens listed above or equivalent regimens~ * Recurrent disease defined as progression more than 2 months after initial therapy and failure to respond (less than 50% reduction or progression in M protein levels) to 1 chemotherapy regimen listed above or other salvage regimens (e.g., high-dose cyclophosphamide or topotecan)~    * Must have received VAD or other equivalent chemotherapy regimen~   * Should be considered for autologous or allogenic transplantation~   * Prior local radiotherapy allowed~PATIENT CHARACTERISTICS:~Age:~* Over 18~Performance status:~* Karnofsky 60-100%~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 2,000/mm\^3\*~* Platelet count at least 50,000/mm\^3\* NOTE: \*Unless attributable to bone marrow infiltration by multiple myeloma~Hepatic:~* Bilirubin less than 3 mg/dL~* Transaminases less than 2.5 times upper limit of normal (ULN)~Renal:~* Creatinine less than 1.5 times ULN OR~* Creatinine clearance at least 60 mL/min~Cardiovascular:~* No cardiac arrhythmias including recurrent supraventricular arrhythmia, any type of sustained ventricular arrhythmia, or conduction block (atrioventricular block grade II or III, left bundle branch block)~* Ejection fraction at least 30%~* No uncontrolled ischemic heart disease~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception during and for 4 months after study~* HIV negative~* No grade 3 or higher neurological disorder, including seizure disorders~* No underlying medical condition that would preclude study~* No other active malignancy except adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~Chemotherapy:~* See Disease Characteristics~* At least 2 weeks since prior chemotherapy~Endocrine therapy:~* See Disease Characteristics~* Concurrent steroid treatment allowed except for primary treatment of myeloma~Radiotherapy:~* See Disease Characteristics~* Concurrent local radiotherapy for pain or symptom control allowed provided the pain or symptom is not related to disease progression~Surgery:~* Not specified~Other:~* No other concurrent ascorbic acid supplements~* No other concurrent investigational drug or therapy~* Concurrent bisphosphonates allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).